Results 181 to 190 of about 286,742 (224)

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2020
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction.
Mathew Maurer, Juan Gimeno Blanes
exaly   +2 more sources

Hypertrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia

Acta Paediatrica, International Journal of Paediatrics, 1993
We report three infants who developed hypertrophic obstructive cardiomyopathy during dexamethasone treatment for bronchopulmonary dysplasia. In all three infants, echocardiography had ruled out cardiac abnormalities prior to the dexamethasone course. The
BRAND, PLP; id_orcid, VANLINGEN, RA, TALSMA, MD, BRUS, F, ELZENGA, NJ   +4 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Dynamic obstruction in hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2015
The present article reviews the recent advances in the echocardiographic assessment of left ventricular outflow tract (LVOT) obstruction in hypertrophic cardiomyopathy (HCM). In particular, it highlights the role of novel imaging techniques in promoting our understanding of the pathophysiology of obstruction and discusses the prognostic value of ...
Bogdan A, Popescu, Monica, Rosca, Ehud, Schwammenthal   +2 more
openaire   +2 more sources

Differential diagnosis of hypertrophic cardiomyopathies: typical (subaortic) hypertrophic obstructive cardiomyopathy, atypical (mid-ventricular) hypertrophic obstructive cardiomyopathy and hypertrophic non-obstructive cardiomyopathy

European Heart Journal, 1983
Previous clinical studies in patients with hypertrophic cardiomyopathies predominantly comprised patients with typical subaortic HOCM and in many other studies patients with 'hypertrophic' cardiomyopathies were investigated; i.e. no distinction was made between patients with the typical obstructive, the atypical obstructive and the non-obstructive ...
H, Kuhn, J, Mercier, E, Köhler, H, Frenzel, W, Hort, F, Loogen   +5 more
openaire   +2 more sources

Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy

The American Journal of Cardiology, 1998
A rare case of obstructive hypertrophic cardiomyopathy (HC) with mitral regurgitation (MR) is reported, which developed over 7 years from nonobstructive HC in an elderly woman. Systolic anterior motion of the anterior mitral leaflet was the most likely cause of the outflow obstruction and mitral valve replacement combined with septal myectomy resulted ...
M, Horimoto, K, Yokota, H, Inoue, T, Takenaka, H, Doi, T, Ohno, M, Sekiguchi   +6 more
openaire   +2 more sources

Prognosis in Hypertrophic Obstructive Cardiomyopathy

Acta Medica Scandinavica, 1979
ABSTRACT Thirty‐eight non‐operated patients with hypertrophic obstructive cardiomyopathy (HOCM) were followed for 1–18 years (mean 8). Twelve patients died, nine of them instantaneously without any other apparent cause of death. The symptoms on the first admission did not discriminate between those who died and those who survived during the observation
openaire   +2 more sources

Interventions in Hypertrophic Obstructive Cardiomyopathy

Canadian Journal of Cardiology
Obstructive hypertrophic cardiomyopathy is the most common genetically transmitted cardiomyopathy that is associated with significant morbidity and mortality. Despite contemporary treatments and interventions, the management of patients with obstructive hypertrophic cardiomyopathy remains poorly defined compared with other branches of cardiology.
Wern Yew, Ding, Mohammed N, Meah, Rodney, Stables, Robert M, Cooper   +3 more
openaire   +2 more sources

Hypertrophic obstructive cardiomyopathy

American Heart Journal, 1972
L A, Jacobs, R D, Yee, P N, Yu
  +6 more sources

Reply: Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy.

JACC. Heart failure
The executive committee of the ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395) trial sincerely thanks Dr Seggewiss for his comments and would like to clarify a few points that he raised. As mentioned in our paper, although sponsored by Bristol Myers Squibb, the trial is directed by an independent academic
Desai, Milind Y, Nissen, Steven E, Abraham, Theodore, Owens, Anjali, Olivotto, Iacopo   +4 more
openaire   +2 more sources

[Hypertrophic obstructive cardiomyopathy].

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1990
Today, with the help of modern echocardiographic techniques we are able not only to describe the characteristic changes when a HOCM is present and to determine the intracavitary pressure gradient, but also recognize the functional irregularities typical for the HOCM.
H, Goos, B, Krosse, P, Ewers
openaire   +1 more source